Developer docs
API playgroundTry for free, no card

Search company profiles

Epiphany

Full company profile

uuid000af7o

Namestring
Epiphany
Websiteurl
epiphanybio.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Epiphany Biosciences is a privately held biotechnology company headquartered in San Francisco, California, founded in 1998. According to the available firmographic data, the company develops therapeutic products and diagnostic technologies intended to prevent or cure the spread of pathogenic viruses, placing it in the antiviral therapeutics and infectious disease diagnostics space.

The company operates with a small headcount of 11–50 employees and is led by founder, chairman, and CEO Fred Volinsky. The firm's only documented material capital event is a March 2007 Series 2 financing of $36 million led by Wexford Capital with participation from CDIB BioScience Ventures. No product approvals, commercial partnerships, clinical trial readouts, or pipeline assets are described in the provided source material, and the company's current operating status, product revenue, and post-2007 corporate activity cannot be confirmed from the available data.

Given the absence of disclosed commercial products, pricing models, customer segments, or distribution channels, the available evidence supports characterization of Epiphany as a small, founder-led, clinical-stage virology R&D entity. The substantial gap between the 2007 funding event and the present suggests either limited public visibility, a quiet operating posture, or a potential stall in disclosed activity, but the input does not allow definitive determination of current commercial trajectory.

Short descriptiontext

Epiphany Biosciences is a privately held, San Francisco-based biotechnology company founded in 1998 that develops antiviral therapeutics and viral diagnostic technologies aimed at preventing or curing the spread of pathogenic viruses.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
antiviral therapeutics, virus diagnostics, biopharmaceutical development, infectious disease treatment, pathogen detection
Industry1 code
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Antiviral Therapeutics and Diagnostics
No data
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Epiphany Biosciences develops therapeutic products and diagnostic technologies focused on preventing or curing the spread of pathogenic viruses. The company combines antiviral drug development with viral detection/diagnostic capabilities to address infectious disease challenges.

Differentiator
Functional benefit
Problem solved
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Clinical-stage immunology company developing antiviral therapeutics and platform approaches against serious infectious diseases. Directly comparable to Epiphany as a focused antiviral therapeutics developer with diagnostic-adjacent capabilities.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapeutics for serious viral infections including COVID-19 and hepatitis C. Directly comparable to Epiphany's antiviral therapeutic focus and small-cap biotech profile.

TypeDirect peer
Description

Clinical-stage biotechnology company developing antiviral therapeutics that target viral replication using structure-based drug design. Comparable as a small-cap antiviral-focused developer with a therapeutic-only platform.

TypeBroad incumbent
Description

Large biopharmaceutical company with a leading antiviral franchise (remdesivir, lenacapavir, hepatitis C portfolio) and broad infectious-disease capabilities. Comparable as the dominant incumbent in antiviral therapeutics.

TypeBroad incumbent
Description

Major biopharmaceutical company developing mRNA-based vaccines and therapeutics for infectious diseases including COVID-19, influenza, and RSV. Comparable in the broader viral infectious-disease therapeutics and vaccines space.

TypeBroad incumbent
Description

Major biopharmaceutical company developing mRNA vaccines and immunotherapies for infectious diseases and oncology. Comparable as a leading developer of vaccines targeting viral pathogens.

TypeBroad incumbent
Description

Large biopharmaceutical company developing antibody-based therapeutics for infectious diseases including Ebola and COVID-19 (REGEN-COV). Comparable as a developer of antiviral biologics.

TypeEmerging player
Description

Biotechnology company developing recombinant nanoparticle vaccines against viral infectious diseases including COVID-19 and influenza. Comparable as a smaller infectious-disease-focused developer targeting viral pathogens.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Epiphany

Antiviral Therapeutics and Diagnosticsepiphanybio.com

Epiphany Biosciences is a privately held, San Francisco-based biotechnology company founded in 1998 that develops antiviral therapeutics and viral diagnostic technologies aimed at preventing or curing the spread of pathogenic viruses.

What Epiphany does

Epiphany Biosciences is a privately held biotechnology company headquartered in San Francisco, California, founded in 1998. According to the available firmographic data, the company develops therapeutic products and diagnostic technologies intended to prevent or cure the spread of pathogenic viruses, placing it in the antiviral therapeutics and infectious disease diagnostics space.

The company operates with a small headcount of 11–50 employees and is led by founder, chairman, and CEO Fred Volinsky. The firm's only documented material capital event is a March 2007 Series 2 financing of $36 million led by Wexford Capital with participation from CDIB BioScience Ventures. No product approvals, commercial partnerships, clinical trial readouts, or pipeline assets are described in the provided source material, and the company's current operating status, product revenue, and post-2007 corporate activity cannot be confirmed from the available data.

Given the absence of disclosed commercial products, pricing models, customer segments, or distribution channels, the available evidence supports characterization of Epiphany as a small, founder-led, clinical-stage virology R&D entity. The substantial gap between the 2007 funding event and the present suggests either limited public visibility, a quiet operating posture, or a potential stall in disclosed activity, but the input does not allow definitive determination of current commercial trajectory.

Epiphany firmographics

Firmographics
Name
Epiphany
Website
https://epiphanybio.com
Company type
Private
Founded year
1998
Headcount range
1–10 employees
Short description
Epiphany Biosciences is a privately held, San Francisco-based biotechnology company founded in 1998 that develops antiviral therapeutics and viral diagnostic technologies aimed at preventing or curing the spread of pathogenic viruses.
Ownership category
akta.pro rank

Epiphany industry classification

Industry
Product category
Antiviral Therapeutics and Diagnostics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Antiviral therapeutics
  • Virus diagnostics
  • Biopharmaceutical development
  • Infectious disease treatment
  • Pathogen detection

Where Epiphany is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Epiphany business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Epiphany product offering

Product offering

Core offering

Epiphany Biosciences develops therapeutic products and diagnostic technologies focused on preventing or curing the spread of pathogenic viruses. The company combines antiviral drug development with viral detection/diagnostic capabilities to address infectious disease challenges.

Differentiator

Problem solved

Functional benefit

Companies that use Epiphany

Customer profile

Ideal customer profiles1 record

Epiphany technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Epiphany partnerships and signals

Strategic signal

Recent moves2 records

Expansion highlights1 record

Epiphany competitors and assessment

Company assessment

Direct peers

  • Vir Biotechnology: Clinical-stage immunology company developing antiviral therapeutics and platform approaches against serious infectious diseases. Directly comparable to Epiphany as a focused antiviral therapeutics developer with diagnostic-adjacent capabilities.
  • Atea Pharmaceuticals: Clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapeutics for serious viral infections including COVID-19 and hepatitis C. Directly comparable to Epiphany's antiviral therapeutic focus and small-cap biotech profile.
  • Cocrystal Pharma: Clinical-stage biotechnology company developing antiviral therapeutics that target viral replication using structure-based drug design. Comparable as a small-cap antiviral-focused developer with a therapeutic-only platform.

Broad incumbents

  • Gilead Sciences: Large biopharmaceutical company with a leading antiviral franchise (remdesivir, lenacapavir, hepatitis C portfolio) and broad infectious-disease capabilities. Comparable as the dominant incumbent in antiviral therapeutics.
  • Moderna: Major biopharmaceutical company developing mRNA-based vaccines and therapeutics for infectious diseases including COVID-19, influenza, and RSV. Comparable in the broader viral infectious-disease therapeutics and vaccines space.
  • BioNTech: Major biopharmaceutical company developing mRNA vaccines and immunotherapies for infectious diseases and oncology. Comparable as a leading developer of vaccines targeting viral pathogens.
  • Regeneron Pharmaceuticals: Large biopharmaceutical company developing antibody-based therapeutics for infectious diseases including Ebola and COVID-19 (REGEN-COV). Comparable as a developer of antiviral biologics.

Emerging players

  • Novavax: Biotechnology company developing recombinant nanoparticle vaccines against viral infectious diseases including COVID-19 and influenza. Comparable as a smaller infectious-disease-focused developer targeting viral pathogens.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Epiphany financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Epiphany leadership team

Management profile

Number of profiles

Profiles1 record

Epiphany funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Epiphany M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epiphany

What does Epiphany do?

Epiphany Biosciences develops therapeutic products and diagnostic technologies focused on preventing or curing the spread of pathogenic viruses. The company combines antiviral drug development with viral detection/diagnostic capabilities to address infectious disease challenges.

When was Epiphany founded?

Epiphany was founded in 1998. It employs 1 to 10 people.

Where is Epiphany based?

Epiphany is headquartered in San Francisco, United States, in the North America region.

Who are Epiphany's main competitors?

Direct peers on record are Vir Biotechnology, Atea Pharmaceuticals and Cocrystal Pharma. Broad incumbents are Gilead Sciences, Moderna, BioNTech and Regeneron Pharmaceuticals. Novavax is listed as an emerging player.

Does Epiphany have an API?

No public API is recorded for Epiphany.

What industry is Epiphany in?

Epiphany's product category is Antiviral Therapeutics and Diagnostics. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireMid-Cities Dermatology Joins Epiphany DermatologyEpiphany Dermatology expanded its Dallas-Fort Worth presence by partnering with Mid-Cities Dermatology, founded in 1977 and led by J. David Miller, MD. The partnership provides Mid-Cities with additional resources for operations and support, while Epiphany gains clinical expertise. The collaboration aims to improve access to dermatologic care in the DFW market.AiThorityMalcolm Harkins Joins Epiphany Systems as Chief Security OfficerMalcolm Harkins will join Epiphany Systems as Chief Security Officer, bringing experience from Cylance and Intel. He will help expand the company's global footprint with its offensive, context-aware cybersecurity platform. Harkins previously served as CISO at Cylance and VP of security at Intel.AL.comWhat is Epiphany?Epiphany is celebrated on Jan. 6, marking the arrival of the magi or Jesus's baptism, depending on tradition. It ends the 12-day Christmas season in Western churches, while Eastern Orthodox commemorate the baptism. The feast dates back to early Christianity, with celebrations extending to Jan. 27 in some traditions.PrwebApplied VTOL Concepts Announces the First Practical Flying CarApplied VTOL Concepts announced the Epiphany flying car, with initial testing planned for early 2021 after a 20-year effort. The vehicle is designed for one or two passengers, uses diesel or bio-fuel, and has an estimated speed of 100+ mph and range of 150+ miles.TechCrunchLessons Learned From My First StartupsThe author recounts his early engineering experiences and two failed startups, Big Crunch and Corensic, before founding Qumulo. He learned that customer feedback is essential, contrasting his earlier visionary approach with his later listening approach. He emphasizes that listening to customers is better than being a visionary founder.GizmodoSatellite Dishes Can Turn Toxic Waste From Fracking Into Clean WaterEpiphany Solar Water Systems in Pennsylvania is testing a device that uses three 8-foot satellite dishes to heat fracking wastewater, distilling pure water and leaving solid salts. The company originally conceived the device for drinking water in developing countries, but fracking industry demand has led to field trials by three gas companies.TechCrunch9 Women Can’t Make a Baby in a MonthMark Suster argues that startups should avoid over-funding early, citing the '9 women can't make a baby in a month' analogy to show markets develop slowly. He warns that excessive capital leads to bad behavior like hiring too fast and forcing market adoption. He hopes entrepreneurs resist VC pressure to over-fund.GlobeNewswireEpiphany Biosciences announces positive results from its phase 2b trial in shinglesEpiphany Biosciences reported positive Phase 2b results for its shingles drug EPB-348, showing once-daily dosing non-inferior to valacyclovir and the 3g dose superior. The study enrolled 373 patients, with no significant adverse events. The company plans Phase 3 trials.GlobeNewswireEpiphany Biosciences plans on filing an IND for valomaciclovir (MIV-606) targeting MSEpiphany Biosciences plans to file an IND at the FDA to study valomaciclovir (MIV-606) in multiple sclerosis patients. The compound, licensed from Medivir, targets EBV and other herpes viruses, which contribute to MS. Valomaciclovir is in phase IIb trials for zoster and phase IIa for mononucleosis.Ars TechnicaProgramming guide: the new text entry features in GTK+ 2.16GTK+ 2.16 released new text entry features, including entry icons and progress bar support. The entry icon API lets developers set icons via pixbuf, stock ID, or icon name, with primary/secondary positions and icon-press signals. Progress bar support includes gtk_entry_set_progress_fraction and pulse-style functions.